Section of'Surgery 255
level of 20% falling to 5 % is sufficient for minor injuries, some sorts of internal bleeding and single tooth extractions; this can be achieved by the use of plasma. For more extensive trauma, such as the extraction of several teeth, one needs 40 % falling to 10%, which requires human AHG, while for major surgery or serious injuries or wounds, 100% falling to 25% is needed and at the moment this can only be achieved by animal AHG. With these high levels, provided they are achieved before operation and maintained by daily injections until healing is complete, the surgeon can really do just what he would do in a patient with normal himostasis but, it must be pointed out, such treatment requires special experience and laboratory facilities, which can be maintained economically only at a small number of centres in this country.
Professor P R Allison (Nuffield Department ofSurgery, Radcliffe Infirmary, Oxford)
Surgery in the Presence of Previously Unsuspected Coagulation Defects
Bleeding which cannot be controlled by the usual mechanical methods of hamostasis is one of the most alarming accidents that can befall a surgeon. It is also one that brings home to us our dependence on the normal processes of coagulation in our everyday work. Fortunately such misfortunes are rare and they can usually be avoided.
Careful questioning should elicit a history of bruising or of abnormal bleeding after tooth extraction but this information may sometimes be withheld unless specifically asked for. Where any such suspicion of coagulation defects is raised it should be pursued before surgery is undertaken, for replacement therapy may make operation safe.
What tests should a surgeon instigate in these circumstances? A platelet count, the bleeding time, the clotting time and the one-and two-stage prothrombin estimations are the usual ones but they are not always enough. The clotting time in hiemophilia may be deceptive. A clumsy venepuncture, especially in a difficult, frightened child, may decrease the-observed clotting time to within normal limits by the addition to the blood of tissue enzymes; such a reading will give a completely false impression of the safety of operation. Furthermore the clotting time in hemophilia is not -prolonged until the level of antihmmophilic globulin (AHG) falls below 1 % in the plasma and major surgery is dangerous when the level is less than 25 %. As there are moderate, bad and worse hlemophiliacs according to the amount of AHG naturally present, it is necessary that the amount present in each patient should be estimated before operation is undertaken if the laboratory is equipped to do this. Such an estimation takes about two hours and, when the condition of the patient is desperate, as for example from a bleeding peptic ulcer, the time can be usefully employed by transfusion of fresh whole blood or plasma. If the laboratory is not equipped to assay AHG the thromboplastin generation test should be done, which takes about one hour.
The estimation of the bleeding time may not always be reliable. In Von Willebrand's disease, for example, this test may show phasic variations and the seriousness of the condition may be greatly affected by an associated AHG deficiency. The treatment of such AHG deficiency is easier than that in htmophilia because the AHG injected is used up more slowly and the injections can be given at longer intervals without the plasma level falling below the base line of 25 %. There is also a suggestion in this disease that bleeding is more likely to occur from mucous membranes than from skin or muscle. It may sometimes be reasonable to make a preliminary incision at the site of operation and to sew it up and wait to see if bleeding occurs. We have done this in one patient who had a coarctation of the aorta: a left thoracotomy incision was made through the skin and the latissimus dorsi muscle and sutured without opening the pleura. As this incision healed perfectly it was reopened a few days later and the coarctation resected successfully.
Anticoagulants and Surgery Numbers of patients are now being treated on 'life-long anticoagulant therapy' for coronary thrombosis, mitral stenosis, chronic pulmonary embolus and thrombophlebitis; it is inevitable that some of these patients will present themselves from time to time for operation. So long as the prothrombin level is not below 20 % major surgery can be undertaken with safety but the level should be checked carefully in the postoperative period to avoid too great a variation.
When anticoagulants of the dicoumarol group are stopped suddenly there is a tendency to an overswing toward vascular thrombosis; if this coincides with an extensive and prolonged opertifie procedure the tendency to thrombosis and pulmonary embolism may be exaggerated. Anticoagulants should therefore be regulated in the post-operative period to maintain a steady state or they should be reduced slowly a short time before operation. If the operation involves the use of heparin as it would, for example, in a patient being subjected to open heart surgery for mitral disease, the dicoumarol drug should be slowly reduced before operation, for the combination of heparin and dicoumarol virtually converts the patient into a hlemophiliac and the postoperative control of bleeding in these circumstances may be very difficult. The usefulness or otherwise of long-term anticoagulant therapy in surgical patients is beyond the terms of reference of this discussion.
Where heparin is required in surgery, the dangers are more those of giving too little than of overdose, if the level in the plasma can be estimated after operation and the requisite quantities of protamine are available for immediate neutralization.
Where open heart surgery is undertaken, entailing as it must full heparinization, postoperative bleeding difficulties have usually been due to incomplete neutralization. It appears as though the body may store heparin in its tissues which it may give back into the plasma later, when perhaps the estimate of heparin in the plasma has already been made, and in this way a rebound heparinization may occur and promote bleeding.
The platelet deficiency that always occurs after extracorporeal circulation is soon remedied by the body and does not usually cause bleeding. Fibrinogen deficiency or the development of abnormal fibrinolysins has on occasions been found to be the cause of bleeding. In such circumstances concentrated fibrinogen has been given with success but sometimes it has been necessary to give 6-aminocaproic acid (EACA).
In the latter event it is advisable to administer the drug before the wound is closed, especially where the pleura has been opened, for otherwise blood in the pleura may form an indissoluble clot which becomes organized and interferes with respiratory function.
The therapeutic use of fibrinolysins such as streptokinase and urokinase in various combinations with anticoagulant drugs for the dissolution of intravascular clots is not yet standardized for surgical use.
Surgery in Hwmophilia
The hemophilic patient may come to the surgeon because of any one of the disorders common to man or because of trouble specifically related to his disease. It has already been stressed that the surgeon should know before operation not only that his patient is a hemophiliac but also the degree of AHG deficiency that normally exists in that particular patient. With this information both the operation and the post-operative care must be planned and carried out in collaboration with the hmematology laboratory. Daily or twice daily investigations at the bedside and in the laboratory are necessary to see the patient through to a soundly healed wound.
There are numerous difficulties in this treatment which need to be stressed: the half-life of AHG is only twelve to fourteen hours so that replacement of AHG must be made often enough to prevent the fall below the baseline of 25%; a discrepancy is found between the actual concentration of AHG in the plasma and that which would be predicted from a given dose ofAHGO; the therapeutic level of AHG reached varies according to whether it is given as plasma, human AHG or animal AHG; the respoinse to a given replacement varies from patient to patient; finally, the response of a given patient to a particular form of AHG varies with time because of the development of antibodies.
For dental extraction where packing and splinting are available bleeding may be controlled by plasma or by fresh whole blood. For a clean surgical incision which is expected to heal by first intention the haemostatic process should be controlled by animal AHG for at least five days but for an operation such as hemorrhoidectomy, where some healing must be by second intention, a programme should be planned for ten to twelve days.
We have observed open wounds in the hbmophiliac for six LO eight weeks and have gained the impression that healing is slower than in normal patients. On the other hand there appears to be no increased tendency to bleed from granulation tissue, so that the dressing of such wounds presents no particular problem. Infection, pain and stiffness in a wound are more likely to throw an increased strain on other muscles and joints and promote bleeding there than to cause bleeding from the wound itself once it is covered by granulation tissue; for this reason we have concluded and found in practice that, where possible, immobilization of the affected part to prevent trauma is a most important item of post-operative management.
The planning of a surgical programme in a himophilic patient is determined by the sources of AHG that are available. These. are fresh whole blood, plasma, human AHG, porcine and bovine AHG. The use of human AHG is limited by its availability: blood from 30,000 donors a year would be required to supply the needs of the country for this. At present only 3,000 donors are used and 80 % of the product goes to Oxford. Its 7 Section of Surgery 257 use is also complicated because of its high fibrinogen content. Fibrinogen is the largest of the plasma protein molecules with a molecular weight of 350,000 and a half-life of five days. As half the AHG disappears from the circulation in twelve hours and half of the associated fibrinogen takes five days it is obvious that the maintenance ofa proper level of AHG results in an ever-increasing concentration of fibrinogen and this may have adverse effects. One of the most interesting pathological and surgical problems specific to the hlmophilic patient is the so-called 'haemophilic cyst': as a result of perhaps trivial injury bleeding may occur beneath the periosteum of a bone, particularly in the pelvis or leg, and spread very slowly causing pressure necrosis wherever it extends. Patients have been seen in whom the cyst has taken twenty-five years to grow to an immense size, extruding into fascial planes between muscles and perforating bones as in a malignant process. Some thrombus formation takes place within the cyst but oozing of blood continues and many pints of fluid blood may be contained in the various loculi of the cyst. The condition may be diagnosed as a malignant tumour and a needle biopsy performed; this causes external bleeding and introduces infection which leads to death. Sometimes the very pressure of the cyst may cause necrosis of the skin and spontaneous rupture. When the condition occurs in the legs it has in the past inevitably led to amputation and this has been undertaken with success. In recent years, however, the blood coagulation research unit in Oxford under the direction of Professor Macfarlane has made it possible to embark on a programme of excision of these cysts with the aim of saving the limbs. The first successful excision was performed in Oxford on December 4, 1959, for a patient in whom the cyst formed a mass in the buttocks and the top of the thigh, extended through the ileum and sacrosciatic foramen into the true pelvis and formed an enormous mass inside the abdomen in the retroperitoneal space. Every loculus was removed by an operation that took ten hours; no limb or organ had to be sacrificed. The first excision of a cyst in the thigh which resulted in the saving of a leg was performed by Mr A J Gunning in Oxford on August 11, 1962. These operations were carried out with control of the hlmostatic mechanism over many weeks. For this purpose all forms of AHG had to be used in succession as resistance to a particular variety occurred. As already indicated, one of the lessons we have learnt is that immobilization of the limb in a plaster case until healing is complete is important in order to avoid fresh bleeding. Altogether 6 such patients have been treated successfully in Oxford.
These cysts might theoretically occur also in Christmas disease but none has so far been observed. In the performance of routine surgical operations in this condition replacement therapy is satisfactory by a concentrate which in addition to Christmas factor also contains Factors X, VII, and prothrombin. The correct dose must be estimated on the assumption that only 20-50 % of what is given can be recovered in the plasma but, as the half-life of Christmas factor is eighteen to thirty hours, the determinations and injections are not as tedious as in hemophilia.
The surgery of these conditions does not differ from that in patients with normally coagulating blood. Surgery is, after all, a more or less standard technique used in association with a knowledge of normal and abnormal function. The effects of variations in technique between one surgeon and another are small compared with those that arise from differences in their appreciation of function. Our interest in and moderate success with these patients is entirely dependent on the specialized 'know how' of Professor Macfarlane and his team.
Professor Sheila Sherlock and Dr L Alpert (Department ofMedicine, Royal Free Hospital, London) Bleeding in Surgery in Relation to Liver Disease Two main problems must be discussed: (1) Surgery in jaundiced patients. (2) Bleeding in those with known abnormal liver function in whom operations are essential.
The liver must be considered in relation to blood coagulation. This can be considered simply as the factors concerned in the one-stage prothrombin time, the usual routine test performed in hospital laboratories. This measures not only prothrombin but also Factors VII, X, V and fibrinogen. It takes no account ofAHG, Christmas factor (Factor IX), Hagemann factor or platelets; AHG is not synthesized by liver and is irrelevant to the present discussion. Christmas factor (and also platelets) may be deficient in patients with liver disease. Hagemann factor deficiency has not been shown in liver disease. For practical purposes the one-stage prothrombin time is a sufficient indication of an adequate clotting mechanism in jaundiced patients. If doubt arises concerning the others the thromboplastin test of Biggs & Douglas (1953) may be performed.
